As the vaccination of immunosuppressed people is insufficiently performed in France, it seems interesting to carry out an evaluation of the situation on the site of the NOVO - Pontoise hospital. The aim of this study is to assess the status of pneumococcal vaccination in patients at the NOVO hospital - Pontoise site, who have received anti-TNF alpha therapy.
Immunosuppressed patients are at risk of infections, sometimes severe with life-threatening consequences. Some of these are vaccine-preventable, notably pneumococcal infections. Specific vaccination recommendations have been published since 2012 by the French High Council for Public Health. However, vaccine coverage is below the desired immunisation objectives for immunosuppressed patients. As the vaccination of immunosuppressed people is insufficiently performed in France, it seems interesting to carry out an evaluation of the situation on the site of the NOVO - Pontoise hospital, in order to propose, if necessary, measures, in particular a specialised consultation, with the aim of improving the vaccination coverage of this population at risk The aim of this study is to assess the status of pneumococcal vaccination in patients who have received anti-TNF alpha therapy.
Study Type
OBSERVATIONAL
Enrollment
106
Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
Internal Medicine Department - NOVO Hospital - Pontoise site
Pontoise, France
Evaluation of the prescription of a pneumococcal vaccination (Conjugated or Unconjugated Pneumococcal Vaccine) by doctors practising at the NOVO Hospital - Pontoise site, in patients receiving anti-TNF alpha treatment
Presence or absence of a prescription or completion of a complete pneumococcal vaccination (Conjugated Pneumococcal Vaccine 13-valent or Unconjugated Pneumococcal Vaccine 23-valent) recorded in the patient's medical file.
Time frame: At the end of the study, an average of one month
Assessment of the timing of the vaccines (Conjugated Pneumococcal Vaccine 13-valent or Unconjugated Pneumococcal Vaccine 23-valent) in relation to the date of initiation of anti-TNF alpha therapy
Number of patients who received a complete pneumococcal vaccination before initiation of treatment and the number of patients who received it after
Time frame: At the end of the study, an average of one month
Assessment of the number of injections prescribed and/or performed (Conjugated Pneumococcal Vaccine 13-valent or Unconjugated Pneumococcal Vaccine 23-valent) for each patient
Number of patients who received an incomplete vaccination scheme (1 dose of Conjugated Pneumococcal Vaccine 13-valent or Unconjugated Pneumococcal Vaccine 23-valent).
Time frame: At the end of the study, an average of one month
Evaluation of the prescription or completion of the vaccination according to the characteristics of the patients and their comorbidities.
Analysis of the data to identify any significant differences according to the characteristics of the vaccinated and non-vaccinated patients (comorbidities, pathology for which the treatment was introduced .....).
Time frame: At the end of the study, an average of one month
Evaluation of the prescription or completion of the vaccination according to the medical specialty of the prescriber
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Analysis of the data to identify any significant differences according to the medical specialty of the prescriber.
Time frame: At the end of the study, an average of one month